Key facts
- It has raised $3.3M across 3 recorded rounds; the latest was Seed Round ($1.0M) in Jun 2020.
- Notable investors include National Institutes of Health, Matter (Consulting Services (B2B)), 2Flo Ventures, Bunker Labs, Francis Wisniewski — 6 tracked in total.
- ResQ Pharma has filed 5 Form Ds with the SEC since 2016, most recently Dec 2024 ($100K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ResQ Pharma
Funding rounds
3 roundsAbout ResQ Pharma
Operator of a clinical-stage pharmaceutical platform intended to develop and commercialize lipid emulsion for the treatment of toxicity caused by lipid-soluble drugs. The company's platform offers a lipid emulsion that can be infused into patients to treat toxicity caused by lipid-soluble drugs which is designed to bind to the toxic drug and prevent it from causing harm, enabling healthcare providers to offer patients effective treatment for various non-opioid drug overdoses.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2010
- Employees
- 3
- Website
- resqpharma.com/
- Ownership
- Privately Held (backing)
ResQ Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ResQ Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ResQ Pharma in its N-PORT filings yet. We sweep new filings monthly.